A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood AdvSep 30, 2026
Clinical ResearchHematologyOncology (Medical)

Andrew M Brunner, Yiwen Liu, Jacqueline S Garcia et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 1b/2 study evaluated ceralasertib, an ATR inhibitor, in 44 adults with relapsed or refractory MDS and CMML. The overall response rate was 29.5%, with a median progression-free survival of 4.8 months and overall survival of 12 months. Two dosing schedules were compared, but no significant differences in outcomes were observed.

Key findings

  • Overall response rate was 29.5% (13/44 patients), including 1 complete response.
  • Median progression-free survival was 4.8 months.
  • Median overall survival was 12 months.
  • Thrombocytopenia requiring transfusion was reduced to 1 of 10 patients on the 7on/7off schedule.

Why it matters

The study provides insights into the efficacy and safety of ceralasertib in a challenging patient population with limited treatment options. Understanding response rates and survival outcomes can inform future therapeutic strategies.

Source

PubMed · PMID 42379235

Published in Blood Adv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.